Pembrolizumab in a Patient with Treatment-Naïve Unresectable BRAF-Mutation Negative Anaplastic Thyroid Cancer

Pembrolizumab in a Patient with Treatment-Naïve Unresectable BRAF-Mutation Negative Anaplastic Thyroid Cancer

Immune check point inhibitor (ICI) therapy can be a potentially effective salvage treatment for anaplastic thyroid cancer (ATC) with progression despite standard of care therapies. We report a case of unresectable treatment-naïve ATC showing a dramatic and durable response to first-line pembrolizuma...

Full description

Bibliographic Details
Main Authors:	Fadi Nabhan, Elizabeth Kander, Rulong Shen, Amit Agrawal, Vineeth Sukrithan, Ye Zhou, Ashima Goyal, Katie Roll, Manisha Shah, Bhavana Konda
Format:	Article
Language:	English
Published:	Hindawi Limited 2021-01-01
Series:	Case Reports in Endocrinology
Online Access:	http://dx.doi.org/10.1155/2021/5521649

Similar Items

Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma
by: Inokuchi J, et al.
Published: (2019-05-01)

Update on the role of pembrolizumab in patients with unresectable or metastatic colorectal cancer
by: Vanessa Wookey, et al.
Published: (2021-06-01)

Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma
by: Priyanka C. Iyer, et al.
Published: (2018-07-01)

Dramatic Response to First Line Single Agent Pembrolizumab in Anaplastic Thyroid Carcinoma
by: Valérie Spalart, et al.
Published: (2019-01-01)

Successful treatment of recurrent unresectable squamous cell carcinoma of the head and neck using pembrolizumab
by: A. M. Mudunov, et al.
Published: (2019-04-01)

Anaplastic Lymphoma Kinase Confers Resistance to BRAF Kinase Inhibitors in Melanoma
by: Radoslav Janostiak, et al.
Published: (2019-06-01)

Single Center Experience Study with Pembrolizumab in Patients with BRAF Mutant Negative Metastatic Melanoma
by: Pejčić Ivica, et al.
Published: (2018-12-01)

Clinical Impact of Sarcopenia and Inflammatory/Nutritional Markers in Patients with Unresectable Metastatic Urothelial Carcinoma Treated with Pembrolizumab
by: Takuto Shimizu, et al.
Published: (2020-05-01)

Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma
by: Ester Simeone, et al.
Published: (2017-03-01)

A phase 2 study of combined chemo-immunotherapy with cisplatin-pembrolizumab and radiation for unresectable vulvar squamous cell carcinoma
by: Oladapo Yeku, et al.
Published: (2020-09-01)

Pathological complete response induced by neoadjuvant treatment using BRAF and MEK inhibitors in a patient with unresectable BRAF V600E-mutant malignant melanoma of the gallbladder
by: Yu Z, et al.
Published: (2018-12-01)

Encorafenib/binimetinib for the treatment of BRAF-mutant advanced, unresectable, or metastatic melanoma: design, development, and potential place in therapy
by: Sun J, et al.
Published: (2018-12-01)

798 Safety, tolerability, and immunogenicity of mRNA-4157 in combination with pembrolizumab in subjects with unresectable solid tumors (KEYNOTE-603): an update
by: Aaron Scott, et al.
Published: (2020-11-01)

Treatment Considerations for Patients with Unresectable Metastatic Melanoma Who Develop Pembrolizumab-Induced Guillain-Barré Toxicity: A Case Report
by: Sivraj Muralikrishnan, et al.
Published: (2020-01-01)

Retrospective analysis of treatment-naive Slovenian patients with metastatic melanoma treated with pembrolizumab – real-world experience
by: Hribernik Nezka, et al.
Published: (2020-01-01)

Squamous Cell Carcinoma of the Thyroid as a Result of Anaplastic Transformation from BRAF-Positive Papillary Thyroid Cancer
by: Alina Basnet, et al.
Published: (2017-01-01)

TREATMENT OF <em>BRAF</em><sup>V600E</sup> POSITIVE ANAPLASTIC THYROID CARCINOMA: CASE REPORT
by: P. A. Nikiforovich, et al.
Published: (2020-10-01)

p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer
by: McFadden, David Glenn, et al.
Published: (2014)

KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma
by: Inge Marie Svane, et al.
Published: (2020-07-01)

Vemurafenib in Chinese patients with BRAF V600 mutation–positive unresectable or metastatic melanoma: an open-label, multicenter phase I study
by: Lu Si, et al.
Published: (2018-05-01)

BRAF activating mutations involving the β3-αC loop in V600E-negative anaplastic pleomorphic xanthoastrocytoma
by: Drew Pratt, et al.
Published: (2018-03-01)

Recurrent extraventricular anaplastic ependymoma with scalp metastasis
by: Amit Agrawal, et al.
Published: (2014-06-01)

Pembrolizumab-induced pneumonitis
by: Vincent Leroy, et al.
Published: (2017-05-01)

Cost-Effectiveness Analysis of Dabrafenib Plus Trametinib and Vemurafenib as First-Line Treatment in Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma in China
by: Tianfu Gao, et al.
Published: (2021-06-01)

Systematic Review and Network Meta-Analysis of Anaplastic Lymphoma Kinase (ALK) Inhibitors for Treatment-Naïve ALK-Positive Lung Cancer
by: Cheng-Hao Chuang, et al.
Published: (2021-04-01)

429 Long-term analysis of MASTERKEY-265 phase 1b trial of talimogene laherparepvec (T-VEC) plus pembrolizumab in patients with unresectable stage IIIB-IVM1c melanoma
by: Antoni Ribas, et al.
Published: (2020-11-01)

PEMBROLIZUMAB IN THE TREATMENT OF METASTATIC MELANOMA
by: I. V. SAMOILENKO, et al.
Published: (2017-06-01)

Pembrolizumab in hemodialysis patients. Is it safe?
by: Melisa Guzmán Vasquez, et al.
Published: (2020-11-01)

Pembrolizumab reactivates pulmonary granulomatosis
by: Majdi Al-dliw, et al.
Published: (2017-01-01)

Neoadjuvant chemotherapy in technically unresectable adenocarcinoma of parotid
by: Sachin Dhumal, et al.
Published: (2019-01-01)

Anaplastic meningioma
by: Xiao-ling YAN
Published: (2014-09-01)

Anaplastic oligodendroglioma
by: Xiao-ling YAN
Published: (2015-02-01)

Anaplastic astrocytoma
by: Xiao-ling YAN
Published: (2014-08-01)

Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial
by: Ian Chau, et al.
Published: (2020-10-01)

BRAF and NRAS Mutations in Papillary Thyroid Carcinoma and Concordance in BRAF Mutations Between Primary and Corresponding Lymph Node Metastases
by: Najla Fakhruddin, et al.
Published: (2017-07-01)

Pembrolizumab Plus Chemotherapy or Anlotinib vs. Pembrolizumab Alone in Patients With Previously Treated EGFR-Mutant NSCLC
by: Ya Chen, et al.
Published: (2021-04-01)

Developments in anaplastic large-cell lymphoma: targeting the anaplastic lymphoma kinase
by: Farina F, et al.
Published: (2014-08-01)

Genetic alterations in anaplastic thyroid carcinoma
by: M Rashid, et al.
Published: (2019-01-01)

Chemoradiation in Unresectable Oral Cavity Cancer: A Myth or Reality!
by: Vijay Maruti Patil, et al.
Published: (2020-10-01)

Unresectable gastrointestinal stromal tumors
by: Prema Menon, et al.
Published: (2011-01-01)

Cannot write session to /tmp/vufind_sessions/sess_o5iljagcumuoj6mhh7oqhlvmu3